Unlocking the power of the immune system against cancer and autoimmune disease

A Global Leader in LAG-3 Immunotherapies for Cancer and Autoimmune Diseases

Immutep is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

Immutep’s diversified product portfolio harnesses LAG-3’s ability to stimulate the immune response to fight cancer or modulate it to combat autoimmune diseases.

more

Our Science

The Company is focused on delivering on immunotherapy’s promise to safely drive superior clinical outcomes for patients and has been pioneering the LAG-3 space for many years.

more

Our Pipeline

Immutep has four clinical-stage assets targeting areas of high unmet need in oncology and autoimmune diseases.

more

Investors & Media

The Company is dedicated to leveraging immunotherapy to develop safe, innovative treatment options for patients and to maximise value to shareholders.

more